"With the most potent weight-loss shot and a pipeline of 11 experimental treatments, including what is widely expected to be the first approved small molecule GLP-1 pill, Eli Lilly stands to be the biggest winner in a market that is projected to grow to $130bn a year in peak sales by the end of the decade"

https://www.ft.com/content/ed81ca79-1fd6-48ea-8e50-246d0849c3f5